Inosiplex treatment of acquired immunodeficiencies: a clinical model for effective immunomodulation. NLM AIDSLINE Important note: Information in this article was accurate in 1986. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Inosiplex treatment of acquired immunodeficiencies: a clinical model for effective immunomodulation.

Methods Find Exp Clin Pharmacol. 1986 Jan;8(1):35-40. Unique Identifier : AIDSLINE MED/86202128
Glasky AJ; Gordon J

Abstract: Patients with various conditions associated with immunologic deficiency (cancer, radiotherapy, surgery, burns, aging, prodromal Acquired Immunodeficiency Syndrome, were treated with inosiplex (INPX) at a dose of 3-4 g/day for periods of time ranging from 1 week to several months. Patients were evaluated clinically, and immunologically with the following assays; natural killer (NK) cytotoxicity, T-lymphocyte count, mitogen-induced proliferation, E rosettes, and skin test reactivity. The data resulting from this large and varied population were quite consistent and reproducible, and indicated that INPX treatment was effective in simultaneously reducing the incidence of complications, infections and mortality while enhancing the immune status of the patient. It has therefore been concluded that an immunopharmacologically active agent such as INPX can elicit important clinical benefits in patients with disorders of diverse etiology, perhaps through modulation of an immunologic defect that is common to a variety of seemingly unrelated conditions.
Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY/IMMUNOLOGY Adult Aged Antineoplastic Agents/ADVERSE EFFECTS Burns/DRUG THERAPY/IMMUNOLOGY Human Immunity/DRUG EFFECTS Immunologic Deficiency Syndromes/*DRUG THERAPY/IMMUNOLOGY Inosine/*ANALOGS & DERIVATIVES Isoprinosine/*THERAPEUTIC USE Kinetics Middle Age Models, Biological Neoplasms/DRUG THERAPY/IMMUNOLOGY Postoperative Complications JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDdrugtherapy/immunologyadultagedantineoplasticagents/adverseeffectsburns/drugtherapy/immunologyhumanimmunity/drugeffectsimmunologicdeficiencysyndromes/KWDdrugtherapy/immunologyinosine/KWDanalogs&derivativesisoprinosine/KWDtherapeuticusekineticsmiddleagemodels,biologicalneoplasms/drugtherapy/immunologypostoperativecomplicationsjournalarticle
860830
M8680256

Copyright © 1986 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1986. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1986. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .